China Cord Blood Corporation (NYSE: CO) got listed on NYSE today. Its stock chart for today is still not available, but the price shoot up 511% and closed at 5.93.

Below is its press release:

BEIJING, Nov. 19 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO; "the Company") today is pleased to announce the successful listing of its ordinary shares on NYSE's main board and the completion of its secondary public offering. The Company's ordinary shares are expected to begin trading on the New York Stock Exchange on November 19, 2009 under the ticker symbol "CO."

The secondary public offering of approximately 3.3 million ordinary shares at US$6.05 per share generated gross proceeds of US$20 million. The proceeds will be applied as working capital and seed capital for ongoing geographical expansion and potential acquisitions in China and the Asia Pacific region. The Company has granted the underwriters a 45-day over-allotment option to purchase up to an additional 495,867 ordinary shares.

"Today marks another milestone in our corporate development history," said Ms. Ting ZHENG, Chairperson and CEO of the Company. "We believe our New York Stock Exchange listing is a recognition of the Company's development over the past few years by our seasoned management team. We also believe that the listing presents us opportunities for our future expansion plan. We will use our best efforts to maintain the course of our business and at the same time seize any new opportunities in China and the Asia Pacific region as they arise."

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM - News), is the lead bookrunner and Macquarie Capital is the joint co-bookrunner for the offering.

The Company's registration statement relating to these securities was declared effective on November 18, 2009 by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A copy of the prospectus relating to the offering may be obtained by visiting EDGAR on the SEC's Web site at http://www.sec.gov , or through Rodman & Renshaw LLC, Prospectus Department, 1251 Avenue of the Americas, New York, NY, 10020, telephone: 212.356.0500 or email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it , or through Macquarie Capitals, Prospectus Department, 125 West 55th St, 22nd Floor, New York, NY 10019, by calling 212.231.6493, by e-mailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

About China Cord Blood Corporation

China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses has been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.

    For more information, please contact:

    Investor & Media Relations:
     China Cord Blood Corporation
     Ms. Joeling Law
     Tel:   +852-3605-8180
     Email: 
  This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 

    Integrated Corporate Relations, Inc.
     In the United States:
     Ashley M. Ammon or Christine Duan
     Tel: +1-646-277-1200

     In China:
     Wei-Jung Yang
     Tel: +86-10-6599-7968

Golden Meditech's Associate Company Listed on NYSE Main Board

Hong Kong, Nov. 19 /PRNewswire-Asia/ -- China's leading high-tech healthcare group, Golden Meditech Company Limited ("Golden Meditech" or "the Group"; Stock Code: 0801.HK) is pleased to announce today that the Group's associate company China Cord Blood Corporation ("CCBC," NYSE: CO) has been listed on the New York Stock Exchange main board (NYSE) under the ticker symbol "CO" after a successful secondary offering. The shares of CCBC started trading at 9:30 am (Eastern Time) on November 19, 2009.

As of today, Golden Meditech holds 44% of CCBC. Based on the offering price of US$6.05 per share, our holding is valued at US$176 million.

As the first umbilical cord blood bank operator in China, CCBC pioneered the commercialization of cord blood storage services in 2003. Over the past six years, CCBC has developed into the largest cord blood bank operator in China in terms of geographical coverage, with exclusive operations in both Beijing and Guangdong Province. In addition, CCBC also owns cord blood bank operations in India, Indonesia, Singapore, the Philippines, Malaysia, China Hong Kong and Australia through an associate company, which makes CCBC the largest cord blood bank in the world in term of total addressable population, geographic coverage, and ethnic groups served.

Investors responded positively to this offering. CCBC issued 3.3 million ordinary shares and raised US$20 million dollars. The offering was handled by renowned investment banks Macquarie Bank and Roadman & Renshaw which are the co-sponsors and co-lead underwriters for this offering.

Mr. KAM Yuen, Chairman and CEO of Golden Meditech, said, "The successful listing of CCBC on the NYSE represents another successful investment that the Golden Meditech management team has made in China's healthcare industry over the past years. It not only signifies the Group's strong execution capability, but also unlocks the value of the underlying business for our shareholders."

Golden Meditech: Golden Meditech was listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited (HKEX) in December 2001, as the first hi-tech medical device enterprise that went public outside of the PRC. It was admitted to the main board in June 2009. During the past few years, thanks to its great efforts in innovation and market expansion, as well as its first-mover abilities in capturing the emerging market opportunities, Golden Meditech's medical devices, cord blood banking services and innovative natural herbal medicines have all established dominant positions in their own sectors. Going forward, Golden Meditech will continue its pursuit of becoming China's leading integrated medical group through organic growth, acquisitions and strategic investments.

    For more information, please contact:

    Investor Relations Division, Golden Meditech Company Limited
     Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
     Tel:     +852-3605-8138
     Fax:     +852-3605-8181
     Email: 
  This e-mail address is being protected from spambots. You need JavaScript enabled to view it